Research graph
References from A phase 1 clinical trial of a multi-antigen SARS-CoV DNA vaccine as a booster after dose three spike-based mRNA vaccinations. Local targets link to admitted publications; unresolved targets remain external evidence.
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
10.1056/nejmoa2102214 · 2021 · External reference
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
10.1056/nejmoa2101544 · 2021 · External reference
Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant
10.1056/nejmoa2103055 · 2021 · External reference
Comparative effectiveness of 3 or 4 doses of mRNA and inactivated whole-virus vaccines against COVID-19 infection, hospitalization and severe outcomes among elderly in Singapore
2022 · External reference
Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections
10.1056/nejmoa2203965 · 2022 · External reference
SARS-CoV-2: The Interplay Between Evolution and Host Immunity
10.1146/annurev-immunol-083122-043054 · 2025 · External reference
Variants and vaccines impact nasal immunity over three waves of SARS-CoV-2
10.1038/s41590-024-02052-z · 2025 · External reference
Structural Immunology of SARS-CoV-2
10.1111/imr.13431 · 2025 · External reference
COVID-19-Associated Hospitalizations Among U.S. Adults Aged ≥18 Years - COVID-NET, 12 States, October 2023-April 2024
10.15585/mmwr.mm7339a2 · 2024 · External reference
Additive effects of booster mRNA vaccination and SARS-CoV-2 Omicron infection on T cell immunity across immunocompromised states
10.1126/scitranslmed.adg9452 · 2023 · External reference
A universal SARS-CoV DNA vaccine inducing highly cross-reactive neutralizing antibodies and T cells
10.15252/emmm.202215821 · 2022 · External reference
Distinct roles of vaccine-induced SARS-CoV-2-specific neutralizing antibodies and T cells in protection and disease
10.1016/j.ymthe.2024.01.007 · 2024 · External reference
Remdesivir for the Treatment of Covid-19 - Final Report
10.1056/nejmoa2007764 · 2020 · External reference
Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial
10.1016/s1473-3099(23)00650-3 · 2024 · External reference
Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373
10.1016/j.vaccine.2023.05.051 · 2023 · External reference
Effectiveness of the fourth dose of COVID-19 vaccines against severe COVID-19 among adults 40 years or older in Brazil: a population-based cohort study
2024 · External reference
Antibody Response After a Fifth Dose (Third Booster) of BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers
10.3390/jcm13216538 · 2024 · External reference
An early warning system for emerging SARS-CoV-2 variants
10.1038/s41591-022-01836-w · 2022 · External reference
Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections
10.1136/gutjnl-2022-327216 · 2023 · External reference
A DNA-based vaccine protects against Crimean-Congo haemorrhagic fever virus disease in a Cynomolgus macaque model
10.1038/s41564-020-00815-6 · 2021 · External reference
Therapeutic DNA vaccination using in vivo electroporation followed by standard of care therapy in patients with genotype 1 chronic hepatitis C
10.1038/mt.2013.119 · 2013 · External reference
SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls
10.1038/s41586-020-2550-z · 2020 · External reference
Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19
10.1016/j.cell.2020.08.017 · 2020 · External reference
Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant
10.1038/s41591-022-01700-x · 2022 · External reference
Memory profiles distinguish cross-reactive and virus-specific T cell immunity to mpox
10.1016/j.chom.2023.04.015 · 2023 · External reference
The SARS-CoV-2 N Protein Is a Good Component in a Vaccine
10.1128/jvi.01279-20 · 2020 · External reference
In vivo Electroporation Enhances the Immunogenicity of Hepatitis C Virus Nonstructural3/4A DNA by Increased Local DNA Uptake, Protein Expression, Inflammation, and Infiltration of CD3+ cells
10.4049/jimmunol.179.7.4741 · 2007 · External reference
